CRVS · Corvus Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$10.45
-0.09 (-0.85%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$886.63M
Shares
84.12M
Volume · Oct 28
306.9K
Avg daily vol (3M)
996.23K
Corvus Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Corvus Pharmaceuticals, Inc. (CRVS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-08-06
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Confident tone
Pipeline Expansion (HS and Asthma)
ANGEL Pharmaceuticals Partnership (China)
Financial Position / Cash Runway
Diluted EPS
$-0.19
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Corvus Pharmaceuticals, Inc. (CRVS) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Corvus Pharmaceuticals, Inc. (CRVS) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-14
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2026 Earnings Call Transcript
Confident tone
ITK mechanism and Treg induction
Phase 2 atopic dermatitis design and timing
Cash runway and financing need
Diluted EPS
$-0.15
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Confident tone
Soquelitinib clinical efficacy in atopic dermatitis
Phase II atopic dermatitis trial
Pipeline expansion to other inflammatory diseases
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript
Confident tone
Soquelitinib atopic dermatitis program
Phase II atopic dermatitis trial design
Peripheral T cell lymphoma (PTCL) Phase III
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript
Confident tone
Soquelitinib in atopic dermatitis
Phase I Cohort 3 efficacy and safety
China partnership with Angel Pharmaceuticals
Diluted EPS
$-0.10
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
Confident tone
Soquelitinib atopic dermatitis Phase 1 efficacy
Phase 2 atopic dermatitis trial planning
Dose selection and pharmacokinetics
Diluted EPS
$-0.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-25
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript
Confident tone
Socalitinib in atopic dermatitis
Socalitinib in T-cell lymphoma (PTCL)
ALPS (NIH trial)
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript
Positive tone
Soquelitinib in atopic dermatitis (Phase I)
December data readout / upcoming catalysts
ITK mechanism and Treg/Th17 biology
Diluted EPS
$-0.60
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call
Diluted EPS
$-0.07
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Call Transcript
Confident tone
Soquelitinib Phase III in PTCL
Soquelitinib in Atopic Dermatitis
Ciforadenant in Renal Cell Cancer
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-19
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
Confident tone
Soquelitinib registrational Phase 3 trial in relapsed PTCL
Phase 1 trial of soquelitinib in atopic dermatitis
Business development and partnering
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.14
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.17
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.32
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.18
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2022 Earnings Call
Diluted EPS
$-0.18
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2021 Earnings Call Transcript
Diluted EPS
$-0.20
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q2
2021-07-15
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2021 Earnings Call
Diluted EPS
$-0.28
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2019 Earnings Call
Diluted EPS
$0.92
Audio
Transcript
Slides
8-K10-K
Showing 1–25 of 25 webcasts
Key facts
CIK
1626971
CUSIP
221015100
13F (30d)
21 filings
21 filers
Visit website
Investor relations